Study Overview: This research is for people with advanced solid tumors, like non-small cell lung cancer (NSCLC), who haven't been cured by other treatments. It's the first time the drug, DS-1062a, is being tested on humans. The study consists of two main parts: Dose Escalation and Dose Expansion. The goal is to find the safest dose and see how well it works on different cancers.
Key Points:
- Study Duration: Expected to last about 6 years, with study sites in the US and Japan.
- Participation Requirements: Multiple visits and tests might be needed. Participants must have advanced cancer that hasn’t responded to other treatments.
- Risks and Benefits: Participants may continue treatment if it's beneficial unless side effects occur or the disease worsens.
Sub-study: A smaller study will compare mouthwashes to prevent mouth sores in participants using DS-1062a. Approximately 76 participants will be involved in this part.
This study is not a quick one. It involves trying to find the best dose and understanding if the treatment works for other cancers too.
How understandable was the trial content above?
Hard to understand
Easy to understand